Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Quick ReadPfizer (PFE) yields nearly 7%, but free cash flow covered only 93% of dividends in 2025, leaving a dangerously thin ...

Pfizer and Valenva are seeking regulatory approval from the Food and Drug Administration for a Lyme disease vaccine in development that's more than 70% effective against the tick-borne illness.

Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

The U.S. might have more doses of Pfizer-BioNTech's COVID-19 vaccine than it thought. While each Pfizer vial is supposed to hold five doses of the first vaccine authorized for emergency use by the ...